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Background: Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to
human disease including cancer. Previous miRNA microarray analysis illustrated that miR-320c is down-regulated in
various cancers. However, the roles of miR-320c in human bladder cancer have not been well elucidated. Therefore,
this study was performed to investigate the biological functions and molecular mechanisms of miR-320c in human
bladder cancer cell lines, discussing whether it could be a therapeutic biomarker of bladder cancer in the future.
Methods: Two human bladder cancer cell lines and samples from thirteen patients with bladder cancer were
analyzed for the expression of miR-320c by quantitative RT-PCR. Over-expression of miR-320c was established by
transfecting mimics into T24 and UM-UC-3. Cell proliferation and cell cycle were assessed by cell viability assay, flow
cytometry and colony formation assay. Cell motility ability was evaluated by transwell assay. The target gene of
miR-320c was determined by luciferase assay, quantitative RT-PCR and western blot. The regulation of cell cycle and
mobility by miR-320c was analyzed by western blot.
Results: We observed that miR-320c was down-regulated in human bladder cancer tissues and bladder cancer cell
lines T24 and UM-UC-3. Over-expression of miR-320c could induce G1 phase arrest in UM-UC-3 and T24 cells, and
subsequently inhibited cell growth. We also indentified miR-320c could impair UM-UC-3 and T24 cell motility. In
addition, we identified CDK6, a cell cycle regulator, as a novel target of miR-320c. Moreover, we demonstrated
miR-320c could induce bladder cancer cell cycle arrest and mobility via regulating CDK6. We also observed that
inhibition of miR-320c or restoration of CDK6 in miR-320c-over-expressed bladder cancer cells partly reversed the
suppressive effects of miR-320c.
Conclusions: miR-320c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating
CDK6. Our study revealed that miR-320c could be a therapeutic biomarker of bladder cancer in the future.
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Urinary bladder cancer is generally accepted as the 11th
most commonly diagnosed type of cancer worldwide [1].
In the US, statistics illustrated that an estimated 74,690
cases were newly diagnosed bladder cancer, among which
15,580 were expected to die in 2014 [2]. Although it is be-
lieved that both environmental [3] and genetic factors* Correspondence: xielp@zjuem.zju.edu.cn
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unless otherwise stated.[4,5], such as genetic polymorphism, chromosomal anom-
alies and epigenetic changes, play critical roles in the de-
velopment of bladder cancer, the exact mechanisms of
bladder carcinogenesis are still not well elucidated. There-
fore, understanding the potential carcinogenetic mecha-
nisms of these genetic changes is important to identify
novel therapeutic targets and prognostic biomarkers.
MicroRNAs (miRNAs) are small (20 ~ 23 nucleotides),
endogenous, non-coding RNAs, which constitute a novel
cluster of target gene regulators [6]. They are involved in vari-
ous cellular processes, including self-renewal, proliferation,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 The oligonucleotides used in this study
Namea Sequence (5′- > 3′)
miR-320c mimics (sense) AAAAGCUGGGUUGAGAGGGU
NC (sense) ACUACUGAGUGACAGUAGA
miR-320c inhibitor ACCCUCUCAACCCAGCUUUU
















aF, forward primer; R, reverse primer.
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gene repression via accelerating the degradation and/or
blocking the translation of their target mRNAs [7]. The
miRNA genes were observed to be specifically deleted
in leukemia initially illustrated the important role of
miRNA in carcinogenesis [8]. Subsequent researches
have demonstrated that the expression of specific miR-
NAs is altered in many types of cancer, which is associ-
ated with carcinogenesis and cancer progression [9-13].
Meanwhile, accumulating evidences illustrated that the
development and progression of bladder cancer is closely
related to the aberrant expression of miRNAs [14]. The
initial study of miRNA expression in bladder cancer was
reported by Gottardo in 2007 and 10 up-regulated miR-
NAs were detected [15].
Previous miRNA microarray analysis illustrated that
miR-320 is down-regulated in breast cancer, acute mye-
logenous leukemia and colon cancer, revealing that miR-
320 could probably act as a tumor suppressor in prohibiting
the behavior of cancer [16-18]. It was reported that
miR-320 could inhibit prostate cancer cell proliferation
by down-regulating the Wnt/beta-catenin signaling path-
way [19]. Additionally, miR-320a/c/d could inhibit the
migration and invasion of hepatocellular cancer via
targeting GNAI1, a crucial protein of multiple cellular
signal transduction pathways [20]. Moreover, Iwagami
et al. showed that miR-320c regulated the resistance of
pancreatic cancer cells to gemcitabine via SMARCC1
(a core subunit of the switch/sucrose nonfermentable),
suggesting that miR-320c could be a potential therapeutic
target in pancreatic cancer [21]. Nevertheless, the po-
tential mechanism of miR-320c in bladder cancer has
not been well elucidated.
In our present study, we further testified miR-320c ex-
pression pattern in bladder cancer tissue. Additionally,
for the first time, we detected that miR-320c could sup-
press growth and motility of the human bladder cancer
cell line T24 and UM-UC-3. The tumor inhibitive role




The miR-320c mimic (named as miR-320c) and the
negative control duplex (named as NC) lacking any sig-
nificant homology to all known human sequences were
used for transient gain of function research. For colony
formation assay, the 2′-O-Methyl modified duplexes of
both miR-320c and NC were used. 2′-O-Methyl modi-
fied miR-320c inhibitor (named as miR-320c-Inh) and
NC inhibitor (named as Inh-NC) were used for observ-
ing the reversed effect of over-expression of miR-320c.
The small interference RNA targeting human CDK6
mRNA (named as siCDK6) was synthesized as describedpreviously [22], which targeted nucleotides 1424–1442
according to Genbank accession NM_001145306.1. All
RNA duplexes were chemically synthesized by Gene-
Pharma Corporation (Shanghai, China). All the applied
sequences were listed in Table 1.
Tissue samples
Paired bladder cancer tissues and para-carcinoma bladder
mucosal tissues were acquired from patients receiving
radical cystectomy. The samples were gained between Jan
2011 and June 2011 from the First Affiliated Hospital,
School of Medicine, Zhejiang University (Hangzhou, P.R.
China) with informed consent and Ethics Committee’s ap-
proval. The clinical data of the patients were listed in
Table 2. All tissue samples were stored in liquid nitrogen
before use.
Cell culture and transfection
The human bladder cancer cell lines UM-UC-3, T24,
and non-tumor urothelial cell line SV-HUC-1 (Shanghai
Institute of Cell Biology, Chinese Academy of Sciences)
were cultured in RPMI1640 medium (Gibco) containing
10% heat-inactivated fetal bovine serum (Gibco), 50U/ml
penicillin and 50 μg/ml streptomycin under a humid at-
mosphere including 5% CO2 at 37°C. Cells were plated
to 60–70% confluency in medium without antibiotics
1 day before transfection. Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA, USA) was selected for trans-
fection under the guide of the instruction.
Table 2 Clinical data of the patients
Patient no. Sex Age TNM stage Histological grade
1 M 62 T2N0M0 III
2 M 60 T1N0M0 I
3 M 53 T1N0M0 III
4 M 86 T1N0M0 III
5 M 55 T1N0M0 II
6 F 74 T2N0M0 III
7 M 56 T2N0M0 III
8 F 76 T3N0M0 III
9 M 65 T2N0M0 II
10 F 69 T2N0M0 II
11 M 72 T3N0M0 III
12 M 78 T1N0M0 II
13 M 76 T3N0M0 III
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Expression level of miR-320c and CDK6 in tissues and cell
lines was calculated by quantitative real-time RT-PCR.
Small RNA was extracted from both frozen samples and
cell lines with RNAiso Kit for Small RNA (TaKaRa, Japan)
and subsequently reverse transcribed into cDNA with One
Step PrimeScript miRNA cDNA Synthesis Kit (TaKaRa,
Japan). Meanwhile, total RNA from cell lines UM-UC-3,
T24, and SV-HUC-1 was extracted using RNAiso plus
(TaKaRa, Japan) and transcribed into cDNA using Prime-
Script RT reagent Kit (TaKaRa, Japan). The resulting
cDNA of miR-320c and CDK6 was quantified by SYBR
Premix Ex Taq (TaKaRa, Japan) via an ABI 7500 fast real-
time PCR System (Applied Biosystems, Carlsbad, USA).
Moreover, the cycle threshold (Ct) value was used for our
analysis (ΔCt), and we determined the expression of small
nuclear RNA U6 and GAPDH mRNA as internal controls
to calculate the relative expression levels of miR-320c and
CDK6 via the 2-ΔΔCt (delta-delta-Ct algorithm) method. All
the primers were listed in Table 1.
Cell viability assay
Each well of 96-well plate was plated with 4000 cells
(UM-UC-3 or T24). After 24 h incubation, the cells were
transfected with RNA duplexes (25–100nM). After 48 h
incubation, medium in each well was removed before
cell counting solution (WST-8, Dojindo Laboratories,
Tokyo, Japan) was added to it and incubated for another
2 h. The absorbance of the solution was measured spec-
trophotometrically at 450 nm with MRX II absorbance
reader (Dynex Technologies, Chantilly, VA, USA).
Colony formation assay
UM-UC-3 and T24 cells were incubated for 24 h after
transfected with 2′-O-Methyl modified duplexes (50nM).Five hundreds of transfected cells were seeded in a new
six-well plate and cultivated continuously for another
10 days. Cells were subsequently treated with methanol
and 0.1% crystal violet for fixing and staining. The colony
formation rate was calculated via the following equation:
colony formation rate = (number of colonies/number of
seeded cells) × 100%.
Cell migration and invasion assay
The 24-well Boyden chamber with 8 μm pore size poly-
carbonate membrane (Corning, NY) was used for evalu-
ating the cell motility. Matrigel was used to pre-coat the
membrane to simulate a matrix barrier for invasion
assay. Four thousands of cells were seeded on the upper
chamber with 200 μl serum-free medium after trans-
fected with RNA duplex for 48 h. 600 μl medium with
20% serum, served as a chemoattractant, was added to
the lower chamber. After 24 h incubation, the mem-
branes were fixed with methanol and stained with 0.1%
crystal violet. Five visual fields (×200) were randomly se-
lected from each membrane, and the cell numbers were
counted via a light microscope.
Cell cycle analysis by flow cytometry
After 48 h transfection, UM-UC-3 and T24 cells were
washed with PBS and fixed in 75% ethanol at −20°C. After
24 h fixation, the cells were washed with PBS and treated
with DNA Prep Stain (Beckman Coulter, Fullerton, CA)
for 30 min. Cell cycle analysis was conducted by BD LSRII
Flow Cytometry System with FACSDiva software (BD Bio-
science, Franklin Lakes, USA). The cell cycle distribution
was illustrated as the percentage of cells in G1, S, and G2
populations and data was evaluated by ModFit LT soft-
ware package.
Protein extraction and Western blotting analysis
After 48 h transfection with RNA duplexes, UM-UC-3
and T24 cells were lysed in cell lysis buffer and concen-
tration of total protein in every lysate was quantified
using the BCA Protein Assay kit (Pierce). Equivalent
amounts (30–50 μg) of protein were separated by 10%
SDS-polyacrylamide gels and transferred to polyvinyli-
dene difluoride membranes. Membranes were blocked
for 1 h with 5% non-fat milk and then incubated at 4°C
overnight with specific primary antibody at appropriate
dilutions according to the instructions. After washed
three times in TBS-Tween, the membranes were incu-
bated with the corresponding horseradish peroxidase
(HRP)-conjugated secondary antibody for 1 h and de-
tected by an enhanced chemi-luminescence (ECL) system
(Pierce Biotechnology Inc., Rockford, IL). The primary im-
munoblotting antibodies used were: anti-GAPDH, anti-
CDK6 (Epitomics, Burlingame, CA).
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In order to construct the luciferase reporter vectors, the 3′-
UTR (untranslated region) of CDK6 was designed (Sangon,
Shanghai, China), which contained putative target region
for miR-320c (sequence set in Table 1). The synthesized
oligonucleotide pair was annealed at 90°C for 3 min and
then transferred to 37°C for another 15 min to form a du-
plex before inserted into pmirGLO Dual-Luciferase miRNA
Target Expression Vector (Promega, USA) between the
SacI and SalI sites. Additionally, the mutant miR-320c puta-
tive target region was also designed, annealed and inserted
into pmirGLO Dual-Luciferase Vector in the same way
(sequence set in Table 1). Both insertions were verified by
sequencing (Sangon, Shanghai, China).
HEK 293 T cells were cultivated in a 24-well plate for
24 h before co-transfected with 50nM of either miR-320c
mimic or NC oligos and 200 ng reporter plasmid contain-
ing wild type (Wt) or mutant type (Mut) of CDK6
3′-UTR. After 48 h transfection, the relative luciferase
activity was calculated by Dual-Luciferase Reporter Assay
System (Promega, USA).
miR-320c inhibitor experiments
To further verify the function of miR-320c, the antisense
inhibitor (miR-320c inhibitor) experiments were performed
to see whether the reverse effects to over-expression could
be observed. The cells were co-transfected with either
miR-320c mimics or NC oligos with miR-320c inhibitor or
NC inhibitor [23]. After 48 h of transfection, colony forma-
tion assay, flow cytometry and transwell assay (cell mi-
gration and invasion assay) was used to analyze the cellFigure 1 miR-320c is down-regulated in bladder cancer Expression le
U6. (A) Individual expression value of miR-320c for both cancer and match
NMIBC and MIBC was shown in a box and whiskers graph. Box-plot lines repr
values, and whiskers indicated 10–90th percentiles. The expression level of m
miR-320c levels in 4 bladder cancer cell lines were lower compared with SV-Hproliferation, cell cycle and cell motility. Besides, ex-
pression level of miR-320c and CDK6 was calculated by
quantitative real-time RT-PCR. In addition, the CDK6 ex-
pression was further determined by Western blotting.
CDK6 rescue experiments
The pTarget-CDK6 plasmid was constructed via inserting
the human CDK6 coding sequence without the 3′-UTR
into the pTarget vector (GeneCopoeia, USA), and verified
by sequencing. The T24 cells were co-transfected with ei-
ther miR-320c mimics or NC oligos with pTarget-CDK6
(pCDK6) or empty pTarget vector (pNull). After 48 h of
transfection, colony formation assay, flow cytometry and
transwell assay was used to evaluate the cell proliferation,
cell cycle and cell motility. Additionally, the CDK6 expres-
sion was determined by Western blotting.
Statistical analysis
All the statistics were expressed as mean ± standard de-
viation (SD) of three independent experiments. Graph-
Pad Prism version 5 for Windows was used to conduct
all the relative analyses via either the student’s t-test or
Two-way ANOVA. P < 0.05 was considered to be statisti-
cally significant.
Results
miR-320c is down-regulated in bladder cancer
The expression pattern of miR-320c in human bladder
cancer has not been analyzed. Therefore, we used real-
time RT-PCR to quantify the expression levels of miR-
320c in 13 pairs of human bladder cancer tissues andvels for miR-320c by real-time PCR analysis were normalized with
ed normal tissues (calculated by 2-ΔCt). (B) The relationship between
esented medians and interquartile ranges of the normalized threshold
iR-320c was significantly lower in MIBC compared with NMIBC. (C) The
UC-1 cell line.
Table 3 Expression value of miR-320c in cancer and
matched normal tissues (normalized by U6 RNA)
Cancer tissues (2-ΔCt) Normal tissues (2-ΔCt) Folds (2-ΔΔCt)
1 0.004581387 0.008668512 0.53
2 0.011048543 0.015517070 0.71
3 0.009226505 0.013696964 0.67
4 0.011280697 0.015843117 0.71
5 0.010525262 0.014578640 0.72
6 0.006258358 0.016064279 0.39
7 0.003569654 0.031034140 0.12
8 0.003721242 0.035402621 0.10
9 0.002008035 0.020617311 0.10
10 0.018073253 0.028955877 0.63
11 0.002800694 0.015303442 0.18
12 0.010096506 0.017701311 0.57
13 0.005083367 0.019505165 0.26
Figure 2 Over-expression of miR-320c suppresses bladder cancer cell
viability was lower in the miR-320c treated groups (cell viability of 0nM was re
wells were presented). The colony formation rate was lower in miR-320c
(representative migration and invasion results at × 200 were presented). (
of miR-320c induced G1-phase arrest in both cell lines (representative his
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non-cancerous counterparts, it was observed that miR-
320c expression levels were lower in cancerous tissues,
and 6 out of 13 samples illustrated a 50% reduction
(Figure 1A). We also illustrated the expression value for
both cancer and matched normal tissues for miR-320c
normalized to U6 RNA in Table 3. In addition, we com-
pared the expression pattern of miR-320c between muscle
invasive bladder cancer (MIBC) and non muscle invasive
bladder cancer (NMIBC), and we found the expression of
miR-320c was lower in MIBC compared to NMIBC,
which indicated that low level of miR-320c could be as-
sociated with tumor aggressiveness and poor prognosis
(Figure 1B). However, such relationship should be fur-
ther verified in a larger sample set in the future. Fur-
thermore, 4 bladder cancer cell lines (UM-UC-3, T24,
5637, J82) demonstrated similar expression pattern of
miR-320c compared with non-tumor urothelial cell line
SV-HUC-1 (Figure 1C). Therefore, it was speculated
that miR-320c could be a potential tumor suppressor in
bladder cancer.proliferation and motility. (A) Cell viability assay. The relative cell
garded as 1.0), respectively. (B) Colony formation assay (representative
treated groups. (C) miR-320c impaired the motility of both cell lines
D) Cell cycle distribution in bladder cancer cell lines. Over-expression
tograms were presented) (*P < 0.05).
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clone formation and triggers G1-phase arrest
In order to understand the potential mechanisms of
miR-320c in tumor suppressing, the bladder cancer cell
lines were transfected with miR-320c to evaluate the ef-
fect of over-expression via cell viability assay. As a result,
miR-320c illustrated a significant inhibitory effect on
bladder cancer cell viability in a dose-dependent manner
(Figure 2A). After 48 h transfection, miR-320c (50nM)
could reduce cell viability in both UM-UC-3 and T24
cell by 35% and 49%, respectively. Furthermore, miR-
320c potently inhibited the colony forming ability in
both cell lines. Compared with cell lines transfected with
NC, the colony formation rate decreased drastically in
those transfected with miR-320c (Figure 2B).
Additionally, in order to better clarify the underlying
mechanisms for miR-320c inhibiting cancer cell prolifer-
ation, we transfected the cells with 50nM miR-320c 48 h
before assessing the impact of miR-320c on cell cycle
distribution via flow cytometry. As a result, we observed
a significant increase in the percentage of cells in the
G1/G0 phase and a decrease in the percentage of cells
in the S and G2/M phase in miR-320c-overexpressingFigure 3 CDK6 is a direct target of miR-320c. (A) An increased expressi
with SV-HUC-1 cells. (B, C) Over-expression of miR-320c reduced CDK6 expres
(D) A predicted seed region in the 3′-UTR of CDK6 was illustratred (top). The
were co-transfected with 50nM of either miR-320c mimic or NC oligos and 20
luciferase activity normalized with Renilla luciferase was calculated 48 h after tcells (Figure 2D). These results suggested that miR-
320c could lead to G1-phase arrest.miR-320c impairs UM-UC-3 and T24 cell motility
To further elucidate the function of miR-320c, we investi-
gated the potential effect of miR-320c on UM-UC-3 and
T24 cell motility. As illustrated by the transwell assay,
over-expression of miR-320c decreased the migration and
invasion of cancer cells compared with NC (Figure 2C).
Therefore, miR-320c negatively regulated the motility of
UM-UC-3 and T24 cells.CDK6 is a key regulator in miR-320c mediated cell
proliferation suppression, cell cycle arrest and cell
motility impairment
We used TargetScan analysis (http://www.targetscan.org),
miRTarBase (http://mirtarbase.mbc.nctu.edu.tw) and Micro-
Cosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/) to detect the potential downstream
targets of miR-320c. Among all the candidate genes
predicted by the online tools, CDK6, a potential down-
stream target of miR-320c, was of particular intereston pattern of CDK6 was observed in UM-UC-3 and T24 cells compared
sion level in both cell lines significantly (levels of mRNA and protein).
mutated sequence was highlighted in underline (bottom). (E) 293 T cells
0 ng plasmid containing Wt or Mut of CDK6 3’-UTR. The relative firefly
ransfection (*P < 0.05).
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scoring predicted binding site and CDK6 was considered to
be a positive cell cycle regulator (G1/S transition) in many
types of cancer [24-26]. Additionally, we also searched for
information on conservation of CDK6 among species. The
NCBI database illustrates that CDK6 gene is conserved in
many species, including chimpanzee, dog, cow, mouse, rat,
zebra fish, fruit fly, mosquito and C.elegans (http://www.
ncbi.nlm.nih.gov/homologene/963). Previous study indi-
cated that the expression of CDK6 increased drastically
in bladder cancerous tissues compared with their non-
cancerous counterparts and elevated CDK6 expression
resulted in the development of bladder cancer [26]. In
our study, an increased expression pattern of CDK6
was observed in the human bladder cancer cell lines
UM-UC-3 and T24 compared with non-tumor urothelial
cell line SV-HUC-1 (Figure 3A). Moreover, we verified
that the expression of CDK6 drastically reduced in both
levels of mRNA and protein after the transfection of
miR-320c, which was consistent with the cell cycle ar-
rest phenomenon (Figure 3B, C).
CDK6 is a novel direct target of miR-320c
In order to clarify whether CDK6 was a direct down-
stream target of miR-320c, the synthesized 3′-UTR of
CDK 6 was cloned into down-stream of firefly luciferaseFigure 4 Ectopic miR-320c expression and inhibition of miR-320c sup
were co-transfected with miR-320c-Inh (vs. Inh-NC) and miR-320c (vs. NC).
(B,C) The expression of CDK6 was determined by real-time PCR and westeof pmirGLO Dual-Luciferase miRNA Target Expression
Vector. Additionally, we also constructed another vector
with mutated putative binding sites (Figure 3D). The re-
sults illustrated that HEK 293 T cells transiently trans-
fected with the Wt-3′- UTR-reporter and miR-320c
exhibited drastically reduced relative luciferase activity
compared with co-transfection of Wt and NC. However,
co-transfection of Mut CDK6 3′-UTR and miR-320c or
NC did not affect the relative luciferase activity (Figure 3E).
Therefore, CDK6 was considered to be a direct down-
stream target of miR-320c based on the luciferase assays.
Inhibition of miR-320c partially reverses the over-
expression of miR-320c induced effects
To better verify the function of miR-320c, the antisense in-
hibitor (miR-320c inhibitor) experiments were performed
to see whether the reverse effects to over-expression could
be observed. As a result, co-transfection of miR-320c-Inh
was applied to attenuate the miR-320c expression promo-
tion and the CDK6 expression inhibition by miR-320c in
the level of mRNA and protein (Figure 4A-C). Further-
more, miR-320c-Inh could partially reverse the effect of
miR-320c on cell proliferation inhibition and cell cycle ar-
rest in the T24 and UM-UC-3 cell lines (Figure 5A,B). A
significant decrease in the percentage of cells in the G1/G0
phase and an increase in the G2/M phase was observed,press the expression of miR-320c and CDK6. T24 and UM-UC-3 cells
(A) The expression of miR-320c was determined by real-time PCR.
rn blot analysis. GAPDH served as an internal control (*P < 0.05).
Figure 5 Inhibition of miR-320c partially reverses the over-expression of miR-320c induced effect. (A, B) Co-transfection of miR-320c-Inh
could partially attenuate the effect of miR-320c on the colony formation rate and cell cycle arrest in the T24 and UM-UC-3 cell lines. (C) The
bladder cancer cells migration and invasion ability was restored after miR-320c-Inh transfection (×200) (*P < 0.05).
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attenuate the G1-phase arrest by miR-320c. Additionally,
the bladder cancer cells migration and invasion ability was
restored after miR-320c-Inh transfection (Figure 5C). Thus,
we confirmed that miR-320c-Inh could reverse the effects
to over-expression of miR-320c.
Repression of CDK6 plays essential roles in miR-320c-
induced bladder cancer inhibition effect
Furthermore, we used loss of function approach to
evaluate whether the physiological function of CDK6
was involved in miR-320c regulated cancer inhibition ef-
fect. The knock-down of CDK6 via RNAi technique dra-
matically decreased the expression of CDK6 in mRNA
and protein levels in both cell lines (Figure 6A,B). More-
over, the transfection of siCDK6 significantly suppressed
the proliferation of bladder cancer cell lines, and we also
observed a significant increase in the percentage of cells
in the G1/G0 phase and a decrease in the S and G2/M
phase, which phenocopied the effects of miR-320c on
bladder cancer cells (Figure 6C-E). Interestingly, the
knock-down of CDK6, generally accepted as a cell cycleFigure 6 Knock-down of CDK6 phenocopied the effect of miR-320c. (
expression of CDK6 (levels of mRNA and protein). (C) SiCDK6 suppressed b
rate in both cell lines (representative wells were presented). (E) SiCDK6 ind
presented). (F) SiCDK6 yield an inhibitory effect on invasion and migrationmediator, also yield an inhibitory effect on cell invasion
and migration (Figure 6F). Therefore, we further verified
that miR-320c inhibited tumorous behaviors of bladder
cancer cells by targeting CDK6.
Restoration of CDK6 expression partially rescues
miR-320c-induced suppression of tumorous behavior
We had verified that over-expression of miR-320c could
induce G1-phase arrest, suppression of cell invasion and
migration before and we wondered whether forced CDK6
expression could abrogate the cell cycle arrest and pro-
mote cell motility by miR-320c. In parallel, co-transfection
of pCDK6 was applied to attenuate the CDK6 expression
inhibition by miR-320c (Figure 7A). Forced CDK6 expres-
sion partially, but significantly, promoted cell proliferation
and motility (Figure 7B, C). We also observed a significant
decrease in the percentage of cells in the G1/G0 phase
and an increase in the G2/M phase, which indicating that
co-transfection of pCDK6 and miR-320c could attenuate
the G1-phase arrest by miR-320c (Figure 7D). Thus, we
confirmed that CDK6 was a key mediator of tumor sup-
pression function of miR-320c in bladder cancer.A, B) The knock-down of CDK6 via RNAi technique reduced the
ladder cancer cell growth. (D) SiCDK6 reduced the colony formation
uced G1-phase arrest in both cell lines (representative histograms were
in both cell lines (×200) (*P < 0.05).
Figure 7 Forced expression of CDK6 partly rescued miR-320c-dependent suppression of tumorous behavior. The T24 cells were co-transfected
with either miR-320c mimics or NC oligos with pTarget-CDK6 or empty pTarget vector. (A) The expression of CDK6 or GAPDH was detected by Western
blot analysis. (B) Forced CDK6 expression partly attenuated the inhibitory effect of miR-320c on the colony formation rate. (C) Co-transfection of pCDK6
partially rescued miR-320c-induced inhibitory effect on cell invasion and migration (×200). (D) Forced expression of CDK6 significantly abrogated cell
cycle arrest effect of miR-320c (*P < 0.05).
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During the past decades, effective targeted therapies of
bladder cancer contributing to improved prognosis were
the highlight of researches [27]. In recent years, a growing
number of researches illustrated that abnormal expression
of miRNAs was considered to be a key regulator in carcino-
genesis [28,29]. Moreover, aberrant expression profiles of
miRNA in cancer detected by microarray analysis provided
deeper insights into the molecular passages of carcinogen-
esis [17,18,30]. A previous systematic review summarized
the dysfunction of miRNAs in bladder cancer, which would
help to establish a mature system in diagnosis and therapy
using miRNAs in the future [14]. However, limited studies
were focused on the regulative functional role of miRNAs
in bladder cancer. The impact of specific miRNAs in blad-
der was still poorly understood. Thereafter, our institution
performed some researches to elucidate the potential rela-
tionship between bladder cancer and miRNAs [31,32].
To the best of our knowledge, we initially detected a
decreased expression pattern of miR-320c in humanbladder cancer tissue compared with its normal adjacent
tissue in the study, Recent miRNA microarray analyses
demonstrated that miR-320 was down-regulated in many
types of cancer, including breast cancer, acute myeloge-
nous leukemia and colon cancer, indicating that miR-
320 could act as a tumor suppressor in cancer, which
was similar to our results [16-18]. Furthermore, previous
studies also revealed that miR-320c could inhibit the
motility of hepatocellular cancer and regulate the resist-
ance of pancreatic cancer cells to gemcitabine [20,21].
However, owing to unique genetic background in differ-
ent types of cancer, the biological function of miR-320c
in bladder cancer was not well elucidated. Therefore, this is
the first study to determine the functional role of miR-320c
in bladder cancer. Considering both of our tissue samples
and cell lines are from patients with muscle-invasive blad-
der cancer, the outcome of this study is probably more
meaningful in muscle-invasive or recurrent cancer.
Our study illustrated that miR-320c was down-regulated
in bladder cancer tissues compared with normal adjacent
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lar result was detected in 4 bladder cancer cell lines com-
pared with non-tumor urothelial cell line SV-HUC-1,
which further strengthened the conclusion that miR-320c
was down-regulated in bladder cancer. A gain-of- function
study was further conducted in bladder cancer cell lines.
When both UM-UC-3 and T24 cells were transfected with
miR-320c, we observed that miR-320c could suppress
bladder cancer cell viability and inhibit clone formation.
In addition, flow cytometry indicated that miR-320c could
trigger G1-phase arrest, which could be the potential
mechanism of miR-320c-regulated proliferation inhibition.
Moreover, cell motility assay demonstrated that over-
expression of miR-320c impaired bladder cancer cells mi-
gration and invasion ability.
To elucidate the possible mechanism responsible for
the anticancer behaviors triggered by miR-320c, we con-
ducted a computerized analysis for the potential target.
Therefore, we identified CDK6 as a new target of miR-
320. A previous study illustrated that CDK6 was over-
expressed in bladder cancer tissue [26]. In our present
study, similar expression pattern of CDK6 was observed
in the human bladder cancer cell lines, which suggested
the oncogenic role of CDK6 in bladder cancer. PCR and
Western blot study indicated that miR-320c could dra-
matically inhibit CDK6 expression and luciferase assay
further confirmed that CDK6 was a downstream target
of miR-320c via directly binding to the 3′-UTR.
To better verify the function of miR-320c, the anti-
sense inhibitor (miR-320c inhibitor) experiments were
performed. We confirmed that miR-320c-Inh could reverse
the effects to over-expression of miR-320c. miR-320c-Inh
could partially reverse the effect of miR-320c on cell cycle
arrest and suppressing cell proliferation and motility.
As a critical cell cycle regulator, CDK6 induces an im-
portant cascade of events in G1-phase. It can modify Rb
phosphorylation efficiently together with CDK4 and cyc-
lin D1, and is considered to a primary sensor for driving
cells through the R point to enter a new round of replica-
tion. Therefore, CDK6 has been regarded as a possible tar-
get for cancer therapy [33]. The knock-down of CDK6 via
RNAi technique illustrated the G1-phase arrest, which
phenocopied the cell cycle arrest effect of miR-320c over-
expression.
Therefore, CDK6 is another important mediator in
miR-320c induced G1/S phase transition arrest and cell
proliferation suppression.
As we mentioned before, the knock-down of CDK6,
generally accepted as a cell cycle mediator, also yielded
an inhibitory effect on cell mobility, which was confus-
ing. Previous studies also indicated that knock-down of
CDK6 could inhibit cell invasion and migration in gas-
tric and Ewing’s Sarcoma [34]. However, the accurate
mechanisms were still unknown. A recent study indicatedthat CDK6, as a key protein, coordinated cell proliferation
and migration in breast cancer mainly dependent on the
expression of estrogen receptor [35]. Furthermore, various
oncogenic signaling pathways, including c-Myc, Ras, and
Neu (ErbB2), have been described to converge on cell
cycle proteins cyclinD1, CDK4/6 expression [36]. The data
presented in our study also identified a novel role for cell
cycle protein CDK6 in bladder cancer through the coord-
ination of cell cycle, migration and invasion.
Ectopic over-expression of CDK6 (without the 3′-
UTR) significantly abrogated the miR-320c-induced G1
arrest of bladder cancer cells and promoted cell prolifer-
ation and motility in vitro. To sum up, these results sug-
gested that miR-320c inhibited the proliferation and
motility of bladder cancer cells via, at least in part, dir-
ectly targeting the 3′-UTR of CDK6. Thus, our current
study revealed what we believed to be a novel upstream
regulatory mechanism of CDK6 in cancer cells.
Conclusions
In conclusion, our study suggests that miR-320c is a po-
tential tumor suppressor in bladder cancer. By targeting
CDK6, miR-320c can inhibit proliferation and impair cell
mobility in bladder cancer cells. Restoration of miR-320c
could be a promising therapeutic strategy for bladder
cancer therapy.
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